Company intelligence / Profile preview
Senti Biosciences
South San Francisco, California, United Statesinvestors.sentibio.com ↗
- Ownership
- Public · SNTI
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
Senti Biosciences’ lead candidate SENTI‑202, an off-the-shelf CAR-NK cell therapy with logic-gated targeting of CD33 OR FLT3 NOT EMCN for AML and other hematologic cancers, has shown promising early results. In the first dose level of its Phase I trial in relapsed/refractory AML patients, two out of three achieved MRD-negative complete remission. The company’s pipeline also includes partnered programs targeting solid tumors such as HCC and tissue-directed gene therapies[2][3][6].
- Therapeutic areas
- Oncology
- Modalities
- Cell therapies (off-the-shelf CAR-NK cells)Gene therapies (Gene Circuits platform)Preclinical work in T cell-based therapies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Spark Therapeutics/RocheBlueRock Therapeutics/BayerCelest Therapeutics[7][8][9]
04
Financials
- Market cap
- $9.3M
- Total revenue
- $17K
- Enterprise value
- $23.1M
Beyond the preview
Go deeper on Senti Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Senti Biosciences.